Literature DB >> 11179476

Interleukin 10 expression is correlated with thrombospondin expression and decreased vascular involvement in colon cancer.

T Kawakami1, T Tokunaga, H Hatanaka, T Tsuchida, Y Tomii, H Osada, N Onoda, F Morino, J Nagata, H Kijima, H Yamazaki, Y Abe, Y Osamura, Y Ueyama, M Nakamura.   

Abstract

Interleukin 10 (IL-10) is an immuno-suppressive cytokine produced by T-lymphocytes, and a regulatory molecule for angiogenesis in various cancers. We examined IL-10 gene expression in 53 colon cancer patients who underwent surgical resection. IL-10 gene expression was correlated with TSP1 and TSP2 gene expression (P=0.0049, P=0.0285). Colon cancer with IL-10 gene expression (19/53) showed significantly decreased venous involvement (P=0.0433). The mean vessel counts in the colon cancers with IL-10 gene expression were significantly lower than those without IL-10 gene expression (P<0.001). These results suggested that IL-10 stimulates angiostatic factor gene expression, and results in suppression of venous involvement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179476     DOI: 10.3892/ijo.18.3.487

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Micro RNA-19a suppresses thrombospondin-1 in CD35+ B cells in the intestine of mice with food allergy.

Authors:  Li-Tao Yang; Xiao-Xi Li; Shu-Qi Qiu; Lu Zeng; Lin-Jing Li; Bai-Sui Feng; Peng-Yuan Zheng; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

2.  A Screening Study of Potential Carcinogen Biomarkers After Surgical Treatment of Obesity.

Authors:  Luciana Teixeira de Siqueira; Marcela Silvestre Outtes Wanderley; Roberto Afonso da Silva; Adriana da Silva Andrade Pereira; José Luiz de Lima Filho; Álvaro Antônio Bandeira Ferraz
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

3.  Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice.

Authors:  Nerida Cole; Mark Krockenberger; Fiona Stapleton; Shamila Khan; Emma Hume; Alan J Husband; Mark Willcox
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

4.  Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Ahmad Shaikh; Purevdorj B Olkhanud; Arunakumar Gangaplara; Abdoul Kone; Sajni Patel; Marjan Gucek; Courtney D Fitzhugh
Journal:  Transplant Cell Ther       Date:  2022-02-04

Review 5.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

6.  Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].

Authors:  Edward L Nelson; Lari B Wenzel; Kathryn Osann; Aysun Dogan-Ates; Nissa Chantana; Astrid Reina-Patton; Amanda K Laust; Kevin P Nishimoto; Alexandra Chicz-DeMet; Nefertiti du Pont; Bradley J Monk
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

7.  Regulation of thrombospondin-1 expression in alternatively activated macrophages and adipocytes: role of cellular cross talk and omega-3 fatty acids.

Authors:  Brian S Finlin; Beibei Zhu; Catherine P Starnes; Robert E McGehee; Charlotte A Peterson; Philip A Kern
Journal:  J Nutr Biochem       Date:  2013-03-22       Impact factor: 6.048

Review 8.  Thrombospondin-1: a physiological regulator of nitric oxide signaling.

Authors:  J S Isenberg; W A Frazier; D D Roberts
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

Review 9.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

10.  Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.

Authors:  Nikolai V Kuznetsov; Arezou Zargari; Alexander W Gielen; Oliver D von Stein; Eugen Musch; Ragnar Befrits; Robert Lofberg; Petra von Stein
Journal:  BMC Gastroenterol       Date:  2014-04-23       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.